ALIS

It was a good month for Insmed Incorporated (NASDAQ: INSM). On Sept. 5, the company released positive phase 3 data for ALIS in the treatment of nontuberculous mycobacterial lung disease, inspiring a doubling in stock price and “elation” in the long-toiling staff. “This data...